

Press release October 23, 2020, 13:00 pm, CET.

Sedana Medical's nomination committee appointed

Sedana Medical AB (publ) today publish that in accordance with the resolution of the Annual General Meeting on May 19, 2020, the Chairman of the Board has contacted the company's three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee.

Sedana Medical's Nomination Committee for the 2020 Annual General Meeting consists of:

- Thomas Eklund, Chairman of the Board
- Karl Tobieson, appointed by Linc AB
- Malin Björkmo, appointed by Handelsbanken Fonder
- Caroline Sjösten, appointed by Swedbank Robur Fonder

Karl Tobieson is appointed chairman of the Nomination Committee.

The Nomination Committee represents 26.7 per cent of all voting rights in the company as of September 30, 2020. The Nomination Committee shall submit proposals for resolution by the 2021 Annual General Meeting pertaining to the election of Chairman of the Board, fees and composition of the Board, auditors' fees and the election of auditors.

Shareholders wishing to submit proposals to Sedana Medical's Nomination Committee can do so by e-mail to corp@sedanamedical.com by January 31, 2021.

For additional information, please contact:
Nomination Committee Chairman, Karl Tobieson
Phone: +46 70 935 85 74
e-mail: karl.tobieson@medcap.se

*Sedana Medical is listed on Nasdaq First North Growth Market Sweden.
Erik Penser Bank (+46 8 463 83 00) is certified adviser to Sedana Medical.*

The information was released for public disclosure, through the agency of the contact person above, on October 23, 2020 at 13:00 pm. (CET).

About Sedana Medical

Sedana Medical AB (publ) has developed and sells the medical device AnaConDa for the administration of volatile anaesthetics. Through a combination of AnaConDa and the candidate drug IsoConDa (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated intensive care patients. The company is working to obtain market approval in Europe for inhaled sedation in intensive care with the pharmaceutical IsoConDa® (isoflurane) during the second half of 2021.

Today, mechanically ventilated intensive care patients are sedated intravenously which leads to several challenges for both patients and care givers. Challenges that are solved by inhaled sedation. Based on an estimate of seven to eight million patients being sedated in intensive care due to mechanical ventilation globally, on average three to four days, Sedana Medical estimates the total market potential to SEK 20-30 billion, evenly distributed between the US, Europe and Asia. Three years after market approval in Europe Sedana Medical expects sales of SEK 500 million in Europe and an EBITDA margin of about 40 percent. The company has initiated a process to obtain market approval in the US in 2024. Registration activities have also been initiated in other markets outside the EU.

Sedana Medical has direct sales in the Nordic countries, Germany, Benelux, France, Great Britain and Spain as well as external distributors in parts of the rest of Europe, Australia, Canada, China, India, Israel, Japan, Mexico and South Korea. The company was founded in 2005 and is headquartered in Stockholm, Sweden, with medical device development in Ireland.